ID7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationConsistent, large FCF supports durable capital flexibility: funds buybacks, dividends, debt paydown, bolt-on M&A and targeted capex without relying on external financing. High cash conversion underpins long-term shareholder returns and resilience through industrial cycles.
Record Orders And Backlog VisibilityStrong, broad-based order intake and elevated backlog provide multi-period revenue visibility and reduce short-cycle volatility. Higher visibility enables capacity planning and supports sustained organic growth and margin stability over the next 2–6+ months.
High-growth Health & Science Technologies ExposureShift toward HST and secular end markets (semiconductor, data centers, space/defense) yields higher growth, recurring revenue and stronger margins. This structural mix improvement makes revenue and earnings less cyclical and more durable over medium term.
Bears Say
Margin Compression Versus Prior PeaksMaterial step-down in margins versus recent peaks suggests lasting pricing, mix or cost pressures. Lower margins reduce intrinsic earnings power and ROE, requiring sustained productivity or higher-margin sales to restore historical profitability levels over time.
Cyclical End-market And Geographic ExposureSubstantial exposure to industrial, short-cycle and regional end markets (including China) creates structural demand variability. Ongoing softness or cautious distributors can dampen order conversion and margin leverage, increasing revenue and profit volatility across quarters.
Lower Returns On Equity Versus Historical LevelsA sustained decline in ROE indicates less efficient capital deployment and weaker incremental returns on invested capital. Even with buybacks and cash generation, persistently lower ROE can limit long-term EPS and shareholder return upside absent structural margin or mix improvements.
IDEX News
ID7 FAQ
What was IDEX Corporation’s price range in the past 12 months?
Currently, no data Available
What is IDEX Corporation’s market cap?
IDEX Corporation’s market cap is CHF13.70B.
When is IDEX Corporation’s upcoming earnings report date?
IDEX Corporation’s upcoming earnings report date is Oct 27, 2026 which is in 88 days.
How were IDEX Corporation’s earnings last quarter?
IDEX Corporation released its earnings results on Jul 29, 2026. The company reported CHF1.891 earnings per share for the quarter, beating the consensus estimate of CHF1.717 by CHF0.174.
Is IDEX Corporation overvalued?
According to Wall Street analysts IDEX Corporation’s price is currently Undervalued.
Does IDEX Corporation pay dividends?
IDEX Corporation does not currently pay dividends.
What is IDEX Corporation’s EPS estimate?
IDEX Corporation’s EPS estimate is 1.8.
How many shares outstanding does IDEX Corporation have?
Currently, no data Available
What happened to IDEX Corporation’s price movement after its last earnings report?
IDEX Corporation reported an EPS of CHF1.891 in its last earnings report, beating expectations of CHF1.717. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of IDEX Corporation?
Currently, no hedge funds are holding shares in CH:ID7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF213.89 (― Upside)
CHF213.89 (― Upside)
Blogger Sentiment
Neutral
CH:ID7 Sentiment 60%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.78%
Trailing 12-Months
Company Description
IDEX Corporation
IDEX Corporation is an international enterprise specializing in engineered solutions across diverse sectors. The company operates through three primary business units: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT division is responsible for the design, production, and distribution of a range of fluid-handling equipment, including positive displacement pumps, flow meters, and injectors, alongside offering flow monitoring and related services. Its applications span the food, chemical, general industrial, water management, agricultural, and energy industries. Under the HST umbrella, IDEX develops and supplies precision components and systems for health and scientific applications. This includes advanced fluidic devices, various types of pumps (rotary lobe, centrifugal, positive displacement), roll compaction and drying technologies, pneumatic components, and sealing solutions, as well as biocompatible medical devices, optical components, and precision photonic solutions. Key markets for this segment encompass food and beverage, pharmaceutical, cosmetics, marine, chemical, wastewater treatment, life sciences, research, and defense. Finally, the FSDP segment delivers critical equipment for emergency services, such as firefighting pumps, valves, rescue tools, and lifting bags. It also provides engineered stainless steel banding and clamping devices for industrial and commercial use, alongside specialized precision equipment for dispensing, metering, and mixing colorants and paints for retail and commercial clients. IDEX Corporation was founded in 1987 and maintains its headquarters in Northbrook, Illinois.
ID7 Company Deck
ID7 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong underlying operational performance and demand momentum, with multiple material positives: organic revenue and EPS growth, significant order expansion (28% overall; HST 47%), margin expansion, record orders and improved leverage and cash generation. Management raised full-year guidance and endorsed continued share repurchases while increasing targeted CapEx to support visible future volumes. Key headwinds were limited: segment-level softness in FMT and FSDP (small or single-digit revenue impacts and margin compression from mix/volume deleverage), and a one-time reporting effect from tariff refunds that reduced reported organic growth by ~2% but provided margin/earnings benefit. Overall the positives materially outweigh the challenges.View all CH:ID7 earnings summariesID7 Net sales Breakdown
35.36% Fluid & Metering Technologies
43.11% Health & Science Technologies
21.53% Fire & Safety/Diversified Products
